Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KW-3902IV for hospitalized heart failure with worsening renal function
NL-OMON31013Phase 3Not yet recruiting
- Sponsor
- NovaCardia
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and cardiorenal syndrome (CRS) comparing KW-3902IV + standard IV diuretic therapy with Placebo + standard IV diuretic therapy (2 arms). Primary endpoint: Treatment failure within 30 days. Planned start Apr 2007; status: not yet recruiting.
02
Drugs
rolofylline
03
Conditions
heart failure (HF)cardiorenal syndrome (CRS)
Beyond the preview
Go deeper on NL-OMON31013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31013.